Drug intelligence / Profile preview

cannabis wound dressing

Development stage: Preclinical
Lead developer: Weed Holdings
Administration: Topical

Overview

Weed Holdings (WEED, Inc.) is developing a cannabis-derived topical wound dressing for the treatment of skin lesions, including basal cell carcinoma and other skin cancers, as well as open wounds. Currently in the preclinical stage, this therapeutic utilizes the medicinal properties of phytocannabinoids to interact with the endocannabinoid system within the skin. The mechanism of action involves the modulation of cannabinoid receptors (CB1 and CB2) to regulate inflammatory pathways, cell proliferation, and apoptosis, potentially inhibiting tumor growth in skin cancers while facilitating tissue repair in chronic wounds.

Other names: cannabis-derived wound dressing

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on cannabis wound dressing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabis wound dressing.

Explore the full profile